WCG
CRBP icon

Weaver Consulting Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Weaver Consulting Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2
Closed – – 285
2020
Q3 		$0 Hold
2
– – ﹤0.01% 967
2020
Q2 		$0 Sell
2
-6
-75% -$1.21K ﹤0.01% 945
2020
Q1 		$1K Buy
8
+1
+14% +$169 ﹤0.01% 756
2019
Q4 		$1K Hold
7
– – ﹤0.01% 788
2019
Q3 		$1K Hold
7
– – ﹤0.01% 770
2019
Q2 		$1K Hold
7
– – ﹤0.01% 759
2019
Q1 		$1K Buy
+7
New +$1.54K ﹤0.01% 1415

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Weaver Consulting Group's CRBP Position: Q4 2020 in Review

Weaver Consulting Group sold out of Corbus Pharmaceuticals (CRBP) in Q4 2020, closing a stake of 2 shares.

Weaver Consulting Group first reported a position in CRBP in Q1 2019 and held it in 7 quarters. The position peaked at $1K in Q1 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q4 2020.

  • Weaver Consulting Group reported no remaining Corbus Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Weaver Consulting Group sold 2 Corbus Pharmaceuticals shares in Q4 2020.
  • Weaver Consulting Group first reported a position in Corbus Pharmaceuticals in Q1 2019 and held it in 7 quarters.
  • Weaver Consulting Group's Corbus Pharmaceuticals position peaked at $1K in Q1 2020.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2020.

Based on Weaver Consulting Group's 13F filing for Q4 2020, filed 29 Jan 2021.